| Literature DB >> 31694687 |
Audrey Y Jung1, Sabine Behrens2, Martina Schmidt3, Kathrin Thoene4, Nadia Obi5, Anika Hüsing2, Axel Benner6, Karen Steindorf3, Jenny Chang-Claude2,4.
Abstract
BACKGROUND: Physical activity (PA) before and after breast cancer diagnosis has been reported to be associated with lower mortality. However, whether changes in the activity after diagnosis impact prognosis is unclear and has not received much attention. This study aimed to examine pre- to postdiagnosis leisure-time PA and breast cancer prognosis.Entities:
Keywords: Breast cancer; Physical activity; Postmenopausal; Prognosis; Survival
Mesh:
Year: 2019 PMID: 31694687 PMCID: PMC6836389 DOI: 10.1186/s13058-019-1206-0
Source DB: PubMed Journal: Breast Cancer Res ISSN: 1465-5411 Impact factor: 6.466
Fig. 1Flow diagram of the inclusion and exclusion criteria for participants of the MARIE study for analyses relating to the changes in physical activity levels and overall mortality, breast cancer mortality, and recurrence-free survival
Postdiagnosis characteristics of the population by change in recommended levels of leisure-time physical activity pre- and postdiagnosis
| Total | Pre- and postdiagnosis leisure-time physical activity | ||||
|---|---|---|---|---|---|
| Insufficiently activea | Increasingly active | Decreasingly active | Sufficiently active | ||
| 2042 (100.0) | 1037 (50.8) | 348 (17.0) | 285 (14.0) | 372 (18.2) | |
| Age at diagnosis, years, median (IQR)b | 62.9 (58.6–66.4) | 63.4 (59.1–67.1) | 61.9 (58.0–65.3) | 64.1 (59.5–67.1) | 61.1 (57.3–64.4) |
| Physical activity prediagnosis, median (IQR) | |||||
| Walking (hours/week)b | 6.0 (3.2–9.0) | 6.0 (3.0–9.0) | 6.0 (3.5–9.0) | 7.0 (3.5–10.5) | 6.0 (3.3–9.0) |
| Cycling (hours/week)b | 1.2 (0.0–3.5) | 1.0 (0.0–3.5) | 1.4 (0.0–4.0) | 1.8 (0.0–4.0) | 2.0 (0.0–4.0) |
| Total (MET-h/week)b | 43.1 (26.5–65.6) | 35.0 (20.0–56.0) | 38.7 (24.2–57.1) | 59.2 (41.1–85.6) | 59.5 (41.7–78.7) |
| Physical activity postdiagnosis, median (IQR) | |||||
| Walking (hours/week)b | 6.0 (3.0–10.0) | 6.0 (3.0–8.0) | 6.0 (4.0–10.0) | 6.0 (3.0–10.0) | 7.0 (4.0–10.0) |
| Cycling (hours/week)b | 1.0 (0.0–3.0) | 0.0 (0.0–2.3) | 2.0 (0.0–4.0) | 1.0 (0.0–3.0) | 2.0 (0.0–3.5) |
| Total (MET-h/week)b | 40.0 (23.4–66.0) | 29.6 (16.0–48.0) | 56.6 (37.3–80.1) | 33.1 (17.2–56.0) | 62.2 (40.3–95.6) |
| BMI, median (IQR)b | 25.3 (22.9–28.4) | 25.8 (23.3–29.4) | 25.0 (22.8–28.3) | 24.8 (22.9–27.7) | 24.4 (22.5–27.1) |
| Smoking status, | |||||
| Never | 1108 (54.3) | 580 (55.9) | 179 (51.4) | 157 (55.1) | 192 (51.6) |
| Former | 748 (36.6) | 341 (32.9) | 141 (40.5) | 105 (36.8) | 161 (43.3) |
| Current | 186 (9.1) | 116 (11.2) | 28 (8.0) | 23 (8.1) | 19 (5.1) |
| Alcohol, g/day, median (IQR)b | 0.7 (0.0–5.7) | 0.6 (0.0–5.4) | 0.7 (0.0–5.7) | 2.0 (0.0–7.1) | 1.4 (0.0–8.3) |
| Education, | |||||
| Less than high/middle school | 1141 (55.9) | 659 (63.5) | 182 (52.3) | 151 (53.0) | 149 (40.1) |
| High/middle school | 583 (28.6) | 268 (25.8) | 108 (31.0) | 79 (27.7) | 128 (34.4) |
| College or university | 318 (15.6) | 110 (10.6) | 58 (16.7) | 55 (19.3) | 95 (25.5) |
| Menopausal hormone use, | 1000 (49.0) | 483 (46.6) | 171 (49.1) | 150 (52.6) | 196 (52.7) |
| Tumour size, cm, | |||||
| < 2 | 1159 (56.8) | 566 (54.6) | 199 (57.2) | 168 (58.9) | 226 (60.8) |
| 2–5 | 622 (30.5) | 336 (32.4) | 101 (29.0) | 86 (30.2) | 99 (26.6) |
| > 5 and growth into chest wall/skin | 73 (3.6) | 46 (4.4) | 11 (3.2) | 8 (2.8) | 8 (2.2) |
| Neoadjuvant chemotherapyc | 61 (3.0) | 32 (3.1) | 11 (3.2) | 6 (2.1) | 12 (3.2) |
| In situ3 | 124 (6.1) | 54 (5.2) | 26 (7.5) | 17 (6.0) | 27 (7.3) |
| Number of positive lymph nodes, | |||||
| 0 | 1322 (64.7) | 690 (66.5) | 209 (60.1) | 170 (59.6) | 253 (68.0) |
| 1–3 | 400 (19.6) | 183 (17.6) | 72 (20.7) | 79 (27.7) | 66 (17.7) |
| > 3 | 135 (6.6) | 78 (7.5) | 30 (8.6) | 13 (4.6) | 14 (3.8) |
| Tumour grade, | |||||
| Low/moderate | 1422 (69.6) | 720 (69.4) | 240 (69.0) | 197 (69.1) | 265 (71.2) |
| High | 426 (20.9) | 223 (21.5) | 71 (20.4) | 64 (22.5) | 68 (18.3) |
| Hormone receptor status, | |||||
| ER+/PR+ | 1238 (60.6) | 628 (60.6) | 208 (59.8) | 175 (61.4) | 227 (61.0) |
| ER+/PR−, ER−/PR+ | 344 (16.8) | 174 (16.8) | 55 (15.8) | 51 (17.9) | 64 (17.2) |
| ER−/PR− | 275 (13.5) | 149 (14.4) | 48 (13.8) | 36 (12.6) | 42 (11.3) |
| HER2 status, | |||||
| HER2+ | 312 (15.3) | 159 (15.3) | 63 (18.1) | 46 (16.1) | 44 (11.8) |
| HER2− | 1413 (69.2) | 715 (68.9) | 228 (65.5) | 197 (69.1) | 273 (73.4) |
| Missing, | 132 (6.5) | 77 (7.4) | 20 (5.7) | 19 (6.7) | 16 (4.3) |
| Type of surgery, | |||||
| Mastectomy | 55 (2.7) | 24 (2.3) | 11 (3.2) | 9 (3.2) | 11 (3.0) |
| Mastectomy + axilla | 478 (23.4) | 266 (25.7) | 85 (24.4) | 57 (20.0) | 70 (18.8) |
| Breast-conserving therapy | 181 (8.9) | 86 (8.3) | 31 (8.9) | 25 (8.8) | 39 (10.5) |
| Breast-conserving therapy + axilla | 1326 (64.9) | 660 (63.6) | 221 (63.5) | 193 (67.7) | 252 (67.7) |
| Mode of tumour detection, | |||||
| Self-detected by palpation/secretion/pain | 1007 (49.3) | 550 (53.0) | 151 (43.4) | 136 (47.7) | 170 (45.7) |
| Routine examination, mammography, ultrasound | 1031 (50.5) | 485 (46.8) | 195 (56.0) | 149 (52.3) | 202 (54.3) |
| Chemotherapy, | 917 (44.9) | 481 (46.4) | 163 (46.8) | 127 (44.6) | 146 (39.2) |
| Radiation therapy, | 1627 (79.7) | 828 (79.8) | 274 (78.7) | 230 (80.7) | 295 (79.3) |
| Hormone therapy, | 1651 (80.9) | 842 (81.2) | 276 (79.3) | 228 (80.0) | 305 (82.0) |
| Diabetes, | 239 (11.7) | 162 (15.6) | 21 (6.0) | 32 (11.2) | 24 (6.5) |
| Cardiovascular disease, | 1349 (66.1) | 737 (71.1) | 227 (65.2) | 180 (63.2) | 205 (55.1) |
| Osteoporosis, | 452 (22.1) | 241 (23.2) | 74 (21.3) | 69 (24.2) | 68 (18.3) |
aInsufficiently active is defined as having between 0 and 7.5 MET-h/week of leisure-time physical activity; sufficiently active is defined as having ≥ 7.5 MET-h/week of leisure-time physical activity
bStatistically significant differences in patient characteristics between physical activity groups tested by ANOVA (p < 0.05 for statistical significance)
cAlso for number of positive lymph nodes, tumour grade, ER/PR status, and HER2 status
Associations between change in pre- and postdiagnosis leisure-time physical activity according to recommendations and overall mortality, breast cancer mortality, and recurrence-free survival in postmenopausal breast cancer survivors
| Pre- to postdiagnosis leisure-time physical activity patterns | Number | Overall mortality | Breast cancer mortality | Recurrence-free survival | |||
|---|---|---|---|---|---|---|---|
| Events | HR (95% CI) | Events | HR (95% CI) | Events | HR (95% CI) | ||
| Insufficiently active | 1021 | 128 | 1.00 (ref.) | 71 | 1.00 (ref.) | 190 | 1.00 (ref.) |
| Increasingly active | 345 | 20 | 0.50 (0.31–0.82) | 14 | 0.54 (0.30–1.00) | 36 | 0.58 (0.40–0.84) |
| Decreasingly active | 281 | 32 | 0.91 (0.61–1.36) | 16 | 0.80 (0.45–1.42) | 54 | 1.04 (0.76–1.43) |
| Sufficiently active | 372 | 26 | 0.75 (0.48–1.15) | 13 | 0.61 (0.33–1.13) | 44 | 0.80 (0.57–1.14) |
Analyses were adjusted for age at diagnosis, tumour size, nodal status, grade, ER/PR status, mode of detection, menopausal hormone use at diagnosis, recurrences between diagnosis and follow-up, and time between recruitment and follow-up, and were stratified by study centre and age at diagnosis in 5-year categories
Time-dependent associations between leisure-time physical activity and overall mortality, breast cancer mortality, and recurrence-free survival in postmenopausal breast cancer survivors
| Physical activity | Number | Events | Overall mortality, HR (95% CI) | Events | Breast cancer mortality, HR (95% CI) | Events | Recurrence-free survival, HR (95% CI) |
|---|---|---|---|---|---|---|---|
| Pre- and postdiagnosis physical activitya,b | Predx/postdx | Predx/postdx | Predx/postdx | Predx/postdx | |||
| No activity | 693/818 | 76/115 | 1.00 (ref.) | 43/64 | 1.00 (ref.) | 115/157 | 1.00 (ref.) |
| Low activity | 692/504 | 73/46 | 0.94 (0.74–1.19) | 43/24 | 0.94 (0.68–1.29) | 115/92 | 1.18 (0.98–1.43) |
| Sufficient activity | 657/720 | 58/46 | 0.73 (0.57–0.93) | 29/27 | 0.64 (0.46–0.89) | 99/80 | 0.82 (0.68–0.99) |
| Prediagnosis physical activityc | |||||||
| No activity | 677 | 73 | 1.00 (ref.) | 41 | 1.00 (ref.) | 112 | 1.00 (ref.) |
| Low activity | 676 | 73 | 1.07 (0.77–1.49) | 43 | 1.18 (0.76–1.83) | 112 | 1.05 (0.80–1.38) |
| Sufficient activity | 647 | 58 | 0.97 (0.68–1.38) | 29 | 0.90 (0.55–1.46) | 97 | 1.04 (0.79–1.37) |
| Postdiagnosis physical activityd in insufficiently active women prediagnosis | |||||||
| No activity | 662 | 91 | 1.00 (ref.) | 53 | 1.00 (ref.) | 121 | 1.00 (ref.) |
| Low activity | 359 | 37 | 0.71 (0.48–1.06) | 18 | 0.65 (0.37–1.16) | 69 | 1.14 (0.84–1.55) |
| Sufficient activity | 345 | 20 | 0.43 (0.26–0.72) | 14 | 0.48 (0.25–0.91) | 36 | 0.59 (0.40–0.86) |
| Postdiagnosis physical activityd in sufficiently active women prediagnosis | |||||||
| No activity | 91 | 23 | 1.00 (ref.) | 10 | 1.00 (ref.) | 34 | 1.00 (ref.) |
| Low activity | 37 | 9 | 0.38 (0.16–0.88) | 6 | 0.69 (0.18–2.56) | 20 | 0.75 (0.41–1.38) |
| Sufficient activity | 20 | 26 | 0.57 (0.30–1.08) | 13 | 0.59 (0.22–1.64) | 44 | 0.65 (0.39–1.09) |
aLeisure-time physical activity in MET-h/week was modelled as a time-dependent variable
bAnalyses were adjusted for age at diagnosis, tumour size, nodal status, grade, ER/PR status, mode of detection, and menopausal hormone use at diagnosis, and were stratified by study centre and age at diagnosis in 5-year categories
cAnalyses were adjusted for age at diagnosis, tumour size, nodal status, grade, ER/PR status, mode of detection, menopausal hormone use at diagnosis, chemotherapy, and hormone therapy, and were stratified by study centre and age at diagnosis in 5-year categories
dAnalyses were adjusted for age at diagnosis, tumour size, nodal status, grade, ER/PR status, mode of detection, menopausal hormone use at diagnosis, and recurrences between diagnosis and follow-up, and were stratified by study centre and age at diagnosis in 5-year categories